Schilsky, Richard L.

American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

Allegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 1,156

Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review

Merker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J., Lindeman, N., Lockwood, C. M., Rai, A. J., Schilsky, R. L., et al. (2018) · Journal of Clinical Oncology

Cancer Genomics and DiagnosticsBRCA gene mutations in cancer

Cited by 959

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 898

Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey

Waterhouse, D. M., Harvey, R. D., Hurley, P., Levit, L. A., Kim, E. S., Klepin, H. D., Mileham, K. F., Nowakowski, G., Schenkel, C., Davis, C., et al. (2020) · JCO Oncology Practice

COVID-19 and healthcare impactsEducation during COVID-19 pandemic

Cited by 199

Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Al Baghdadi, T., Halabi, S., Garrett-Mayer, E., Mangat, P. K., Ahn, E. R., Sahai, V., Alvarez, R. H., Kim, E. S., Yost, K. J., Rygiel, A. L., et al. (2019) · JCO Precision Oncology

Pancreatic and Hepatic Oncology ResearchAdvanced Breast Cancer Therapies

Cited by 94

A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital

INNOCENTI, F., UNDEVIA, S., RAMIREZ, J., MANI, S., SCHILSKY, R., VOGELZANG, N., PRADO, M., & RATAIN, M. (2004) · Clinical Pharmacology & Therapeutics

Cancer therapeutics and mechanismsPharmacogenetics and Drug Metabolism

Cited by 57

Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.

Gupta, R., Garrett-Mayer, E., Halabi, S., Mangat, P. K., D'Andre, S. D., Meiri, E., Shrestha, S., Warren, S. L., Ranasinghe, S., & Schilsky, R. L. (2020) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 41

Phase II study of echinomycin in patients with advanced breast cancer: a report of Cancer and Leukemia Group B protocol 8641

Schilsky, R. L., Faraggi, D., Korzun, A., Vogelzang, N., Ellerton, J., Wood, W., & Henderson, I. C. (1991) · Investigational New Drugs

Breast Cancer Treatment StudiesCancer Treatment and Pharmacology

Cited by 21

A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology

Lazar, V., Zhang, B., Magidi, S., Le Tourneau, C., Raymond, E., Ducreux, M., Bresson, C., Raynaud, J., Wunder, F., Onn, A., et al. (2023) · Therapeutic Advances in Medical Oncology

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 14